Despite discordances regarding the relationship between CSPG4 expression and KMT2A fusions, differences in 7.1 reactivity in KMT2A-r ALL and AML supports the importance of the identification of alternative markers for prediction of KMT2A-r. The gene discussed is CSPG4; the disease is acute myeloid leukemia.